I think their data to date looks reasonable. As I mentioned earlier, I like their approach of reducing force production.
The targeted hypertrophic cardiomyopathy angle did turn out to be bunk, since they don't seem to be focusing on a mutation-driven strategy. I actually think that's a good thing.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.